Effect Of Nigella Sativa Oil for the Treatment of Hypertension

My research explores the antihypertensive effects of Nigella sativa (black seed) oil in managing high blood pressure. Hypertension is a growing global health concern, often insufficiently controlled by standard medications. Nigella sativa, known for its bioactive compound thymoquinone, possesses antioxidant, anti-inflammatory, and vasodilatory properties, making it a potential natural remedy for blood pressure regulation.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bahria Town

Lahore, Punjab Province, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 30 to 70 years
Diagnosed with mild to moderate hypertension (BP ≥140/90 mmHg)
Willing to participate and provide written informed consent
Not currently on any herbal or nutritional supplements

Exclusion criteria

History of smoking or alcohol consumption
Pregnant, postmenopausal, or breastfeeding women
Use of dietary supplements or medications containing antioxidants, caffeine, estrogen, or steroids
Individuals engaging in regular vigorous physical exercise
Those adding extra salt to their meals
Known allergy to Nigella sativa or black seed oil

Treatment and study plan

Nigella sativa (black seed)

Combination Product

Participants in Group 1 (intervention group) will receive Nigella sativa (black seed) oil at a dosage of 0.5 ml, administered orally twice daily-once before breakfast and once before bedtime-for a duration of 12 weeks. The oil, sourced from a standardized local supplier, is rich in thymoquinone, known for its antioxidant and vasodilatory properties. Blood pressure will be measured at baseline and biweekly intervals using a calibrated digital sphygmomanometer to monitor changes in systolic and diastolic values. Participants will also be monitored regularly for any adverse effects.

Primary outcomes

Structured Patient History Questionnaire

Time frame: 12 Months

A pre-designed, structured questionnaire will be used at baseline to collect demographic information, medical history, medication use, dietary habits, and lifestyle factors. This is a qualitative tool without a scoring system but is essential for eligibility confirmation and contextual analysis

Sponsors and collaborators

Lead sponsor

Superior University

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2026
First posted: Jul 9, 2025
Registry last updated: Jul 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting